Cero Therapeutics downgraded to Hold from Buy at D. Boral Capital

D. Boral Capital downgraded Cero Therapeutics (CERO) to Hold from Buy without a price target The decision to execute another reverse stock split reflects Cero’s commitment to adhering to Nasdaq’s minimum bid price criteria, the analyst tells investors in a research note. The firm says stocks typically need time to stabilize post-split and rarely experience material performance improvement “until a clear catalyst emerges that can drive a re-rating of valuation.”